KRT18 and COVID-19: This was unexpected, given that other studies have reported benefits in immune responses with D + Q treatment in infections like COVID‐19, using models like the K18‐ACE2 transgenic mouse and human brain organoids (Aguado et al. 2023; Pastor‐Fernández et al. 2023).